This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vuist, W. M. J. Articles by Melief, C. J. M. Search for Related Content PubMed PubMed Citation Articles by Vuist, W. M. J. Articles by Melief, C. J. M.

Potentiation by Interleukin 2 of Burkitt's Lymphoma Therapy with Anti-Pan B (Anti-CD19) Monoclonal Antibodies in a Mouse Xenotransplantation Model

Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands [W. M. J. V., F. v. B., A. H., P. R., C. J. M. M.], and Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Division of Clinical Immunology, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands [M. A. d. R.]

To study the immunotherapeutic potential of monoclonal antibodies (mAbs) directed against the human pan-B-cell antigen CD19, a xenotransplantation model was developed in which the human Burkitt's cell line Daudi is s.c. transplanted into nude mice.

IgG1, IgG2b, and IgG2a isotype variants of the anti-CD19 mAb (CLB-CD19) were tested for their capacity to inhibit the growth of 10 x 10⁶ Daudi cells injected s.c. into nude mice. When mAb treatment was started 30 min after the injection of tumor cells, only the IgG2a isotype of CLB-CD19 had a marked antitumor effect in vivo. If treatment with IgG2a anti-CD19 mAb alone was delayed until Day 10 after tumor injection, no therapeutic effect was observed. However, the combination of this delayed mAb treatment with recombinant interleukin 2 (rIL-2) inhibited the growth of the Daudi cells in the nude mice, while treatment with rIL-2 alone was ineffective.

The results of in vitro experiments showed that peritoneal exudate cells were able to inhibit the proliferation of Daudi cells in the presence of the IgG2a isotype variant of CLB-CD19 mAb but not in the presence of the other CLB-CD19 mAb isotype variants.

Fresh nude mouse spleen cells did not mediate antibody-dependent cellular cytotoxicity against CLB-CD19 mAb-sensitized Daudi cells, irrespective of the isotype used for sensitization. However, preculture of these spleen cells with rIL-2 induced antibody-dependent cellular cytotoxicity against CD19⁺ target cells sensitized with CLB-CD19 mAb of all isotypes.

These results indicate that it is possible to enhance mAb-dependent effector systems in vivo with the lymphokine rIL-2.

¹ Supported by a grant from the Koningin Wilhelmina Fonds (The Netherlands Cancer Foundation), Grant NKI 84-14. To whom requests for reprints should be addressed.

Received 10/18/88. Revised 3/ 2/89. Accepted 3/28/89.

This article has been cited by other articles:

				J. Kurai, H. Chikumi, K. Hashimoto, K. Yamaguchi, A. Yamasaki, T. Sako, H. Touge, H. Makino, M. Takata, M. Miyata, et al. Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines Clin. Cancer Res., March 1, 2007; 13(5): 1552 - 1561. [Abstract] [Full Text] [PDF]

				N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease PNAS, October 18, 2005; 102(42): 15178 - 15183. [Abstract] [Full Text] [PDF]

				J. L. Hornick, L. A. Khawli, P. Hu, M. Lynch, P. M. Anderson, and A. L. Epstein Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 With Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions While Retaining Tumor Targeting Properties Blood, June 15, 1997; 89(12): 4437 - 4447. [Abstract] [Full Text] [PDF]